within Pharmacolibrary.Drugs.ATC.J;

model J01DI04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 8.633333333333332e-05,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0135,
    k12             = 16.6,
    k21             = 16.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DI04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cefiderocol is a novel siderophore cephalosporin antibiotic approved for the treatment of serious Gram-negative bacterial infections, including those caused by carbapenem-resistant organisms. It is administered intravenously and is indicated for use in complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia (HABP), and ventilator-associated bacterial pneumonia (VABP).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Zhanel, GG, Golden, AR, Zelenitsky, S, Wiebe, K, Lawrence, CK, Adam, HJ, Idowu, T, Domalaon, R, Schweizer, F, Zhanel, MA, Lagacé-Wiens, PRS, Walkty, AJ, Noreddin, A, Lynch Iii, JP, &amp; Karlowsky, JA (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> 79(3) 271–289. DOI:<a href=\"https://doi.org/10.1007/s40265-019-1055-2\">10.1007/s40265-019-1055-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30712199/\">https://pubmed.ncbi.nlm.nih.gov/30712199</a></p></li><li><p>Miyazaki, S, Katsube, T, Shen, H, Tomek, C, &amp; Narukawa, Y (2019). Metabolism, Excretion, and Pharmacokinetics of [. <i>Journal of clinical pharmacology</i> 59(7) 958–967. DOI:<a href=\"https://doi.org/10.1002/jcph.1386\">10.1002/jcph.1386</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30730562/\">https://pubmed.ncbi.nlm.nih.gov/30730562</a></p></li><li><p>Sanz-Codina, M, van Os, W, Pham, AD, Jorda, A, Wölf-Duchek, M, Bergmann, F, Lackner, E, Lier, C, van Hasselt, JGC, Minichmayr, IK, Dorn, C, Zeitlinger, M, &amp; Al Jalali, V (2024). Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers. <i>The Journal of antimicrobial chemotherapy</i> 79(12) 3281–3288. DOI:<a href=\"https://doi.org/10.1093/jac/dkae359\">10.1093/jac/dkae359</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39373642/\">https://pubmed.ncbi.nlm.nih.gov/39373642</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DI04;
